ALIM Alimera Sciences Inc.

1.33
+0.02  (2%)
Previous Close 1.31
Open 1.32
Price To book -1.96
Market Cap 91837303
Shares 69,050,604
Volume 251,052
Short Ratio 4.22
Av. Daily Volume 152,992

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171134329
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021536
  3. 8-K - Current report 171002982
  4. 8-K - Current report 17958400
  5. 8-K - Current report 17927862

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. ETFs with exposure to Alimera Sciences, Inc. : October 10, 2017
  2. Alimera Sciences Announces Four Data Sets for ILUVIEN® to Be Presented at 2017 Retina Society’s Annual Meeting
  3. ETFs with exposure to Alimera Sciences, Inc. : September 29, 2017
  4. Alimera Sciences to Present at the Sidoti & Company Fall 2017 Conference
  5. Alimera Sciences Announces ILUVIEN® now available in Ireland
  6. Weather Related Conditions Cancels Alimera Sciences Presentation at Rodman & Renshaw Global Investment Conference
  7. Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 7, 2017
  8. Alimera Sciences Announces 9 Clinical Presentations and a Sponsored Symposium at 17th Euretina Congress
  9. Alimera Sciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
  10. Edited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT
  11. Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting
  12. Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017
  13. Alimera Sciences reports 2Q loss
  14. Investor Network: ALIMERA SCIENCES INC to Host Earnings Call
  15. Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment
  16. Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017
  17. ETFs with exposure to Alimera Sciences, Inc. : July 13, 2017